Division of Gastroenterology, Sunnybrook Health Sciences Centre.
In Vitro Drug Safety and Biotechnology and Department of Pharmacology and Toxicology, University of Toronto.
J Pharm Pharm Sci. 2020;23:301-313. doi: 10.18433/jpps31242.
Cannabis has been used for its medicinal purposes since ancient times. Its consumption leads to the activation of Cannabis receptors CB1 and CB2 that, through specific mechanisms can lead to modulation and progression of inflammation or repair. The novel findings are linked to the medical use of Cannabis in gastrointestinal (GI) system.
The objective of the present paper is to elucidate the role of Cannabis consumption in GI system. An additional aim is to review the information on the function of Cannabis in non-alcoholic fatty liver disease (NAFLD).
This review summarizes the recent findings on the role of cannabinoid receptors, their synthetic or natural ligands, as well as their metabolizing enzymes in normal GI function and its disorders, including irritable bowel syndrome (IBS), inflammatory bowel disease (IBD) and possible adverse events. The synergism or antagonism between Cannabis' active ingredients and the "entourage" plays a role in the efficacy of various strains. Some elements of Cannabis may alter disease severity as over-activation of Cannabis receptors CB1 and CB2 can lead to changes of the commensal gut flora. The endocannabinoid system (ECS) contributes to gut homeostasis. The ability of ECS to modulate inflammatory responses demonstrates the capacity of ECS to preserve gastrointestinal (GI) function. Alterations of the ECS may predispose patients to pathologic disorders, including IBD. Clinical studies in IBD demonstrate that subjects benefit from Cannabis consumption as seen through a reduction of the IBD-inflammation, as well as through a decreased need for other medication. NAFLD is characterized by fat accumulation in the liver. The occurrence of inflammation in NAFLD leads to non-alcoholic-steatohepatitis (NASH). The use of Cannabis might reduce liver inflammation.
With limited evidence of efficacy and safety of Cannabis in IBD, IBS, and NAFLD, randomized controlled studies are required to examine its therapeutic efficacy. Moreover, since long term use of the plant leads to drug use disorders the patients should be followed continuously.
自古以来,大麻就因其药用价值而被使用。其消费导致大麻受体 CB1 和 CB2 的激活,通过特定的机制可以导致炎症的调节和进展或修复。新的发现与大麻在胃肠道 (GI) 系统中的医学用途有关。
本文的目的是阐明大麻消费在胃肠道系统中的作用。另一个目的是综述大麻在非酒精性脂肪性肝病 (NAFLD) 中的作用的信息。
本综述总结了大麻素受体、其合成或天然配体以及代谢酶在正常胃肠道功能及其疾病中的最新发现,包括肠易激综合征 (IBS)、炎症性肠病 (IBD) 和可能的不良事件。大麻的活性成分及其“伴随物”之间的协同作用或拮抗作用在各种菌株的疗效中发挥作用。大麻的某些元素可能会改变疾病的严重程度,因为大麻受体 CB1 和 CB2 的过度激活会导致共生肠道菌群的变化。内源性大麻素系统 (ECS) 有助于肠道内稳态。ECS 调节炎症反应的能力表明 ECS 保持胃肠道 (GI) 功能的能力。ECS 的改变可能使患者易患病理疾病,包括 IBD。IBD 的临床研究表明,患者从大麻消费中受益,如 IBD 炎症减少,以及对其他药物的需求减少。NAFLD 的特征是肝脏脂肪堆积。NAFLD 中的炎症会导致非酒精性脂肪性肝炎 (NASH)。大麻的使用可能会减轻肝脏炎症。
由于大麻在 IBD、IBS 和 NAFLD 中的疗效和安全性证据有限,需要进行随机对照研究来检查其治疗效果。此外,由于长期使用该植物会导致药物使用障碍,因此应持续对患者进行随访。